scholarly journals Biological variability in serum vitamin E concentrations: relation to serum lipids

1996 ◽  
Vol 42 (11) ◽  
pp. 1824-1831 ◽  
Author(s):  
M Maes ◽  
S Weeckx ◽  
A Wauters ◽  
H Neels ◽  
S Scharpé ◽  
...  
Keyword(s):  
Vitamin E ◽  
Serum Lipids ◽  
Low Density Lipoprotein ◽  
Serum Vitamin ◽  
Density Lipoprotein ◽  
Low Density Lipoprotein Cholesterol ◽  
Apo B ◽  
Positive Time ◽  
Index Of Individuality ◽  
The Mean

Abstract The components of biological variation in serum vitamin E in relation to serum cholesterol, triglycerides, high- and low-density lipoprotein cholesterol (HDL-C, LDL-C), apolipoprotein A-I (apo A-I), and apo B were examined in 26 healthy volunteers who had monthly blood samplings during one calendar year. The estimated CVs for vitamin E were: interindividual, 19.9%, and intraindividual, 11.9%; the index of individuality (I-index) was 0.59. The I-indices for all lipid variables were < 0.51. Serum concentrations of vitamin E, cholesterol, triglycerides, HDL-C, LDL-C, and apo B were lower in spring than in the other seasons. The peak-trough differences in the yearly variations, expressed as a percentage of the mean, were for vitamin E 14.5%, cholesterol 16.2%, triglycerides 14.5%, and LDL-C 24.3%. A significant common annual rhythm was expressed in vitamin E or lipid variables and in the changes in ambient temperature the weeks before blood sampling (inverse relations). There were highly significant positive time relations between serum vitamin E and cholesterol, triglycerides, and apo B. Subjects with higher homeostatic setpoints of cholesterol showed higher homeostatic setpoints of vitamin E, triglycerides, LDL-C, and apo B.

scholarly journals Evolution of serum lipids in two male bodybuilders using anabolic steroids

1996 ◽  
Vol 42 (6) ◽  
pp. 970-972 ◽  
Author(s):  
F Lajarin ◽  
R Zaragoza ◽  
I Tovar ◽  
P Martinez-Hernandez
Keyword(s):  
Anabolic Steroid ◽  
Serum Lipids ◽  
Anabolic Steroids ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density Lipoprotein Cholesterol ◽  
Steroid Use ◽  
Apo B ◽  
Drug Cessation

Abstract We followed weekly the evolution of serum lipid concentrations in two bodybuilders undergoing a cycle of treatment with anabolic steroids. These drugs caused maximum depression of high-density lipoprotein cholesterol concentrations by 69.1% in the fifth week after the beginning of the cycle for subject 1, and by 72.4% in the fourth week for subject 2. Maximum increases in low-density lipoprotein cholesterol concentrations were 144% and 156%, respectively. Total cholesterol and apolipoprotein (apo) B were highly increased with anabolic steroid use. We also saw depression of apo A-I by 84% and 91%, and lipoprotein(a) decreased to undetectable amounts in both cases. These effects were reversed 10 weeks after the end of the steroid cycle in subject 1, but subject 2 still presented abnormal concentrations of serum lipids 13 weeks after drug cessation. The periods until reversibility of anabolic steroid effects on lipids were longer than those reported in previous studies.

Effect of thyroid function on concentrations of lipoprotein(a)

1993 ◽  
Vol 39 (12) ◽  
pp. 2466-2469 ◽  
Author(s):  
H Engler ◽  
W F Riesen
Keyword(s):  
Thyroid Hormones ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density Lipoprotein Cholesterol ◽  
Apo B ◽  
Thyroid State ◽  
Lipoprotein A ◽  
The Mean ◽  
L 14 ◽  
Rule Out

Abstract The effect of thyroid hormones on concentrations of lipoprotein(a) [Lp(a)] was analyzed in 60 patients with active thyroid dysfunction (hyperthyroidism 30 cases, hypothyroidism 32 cases, and 2 cases with opposite changes) and after normalization of the thyroid state. Treatment of hyperthyroidism increased the mean Lp(a) concentrations by 60% (from 73 to 102 mg/L, P < 0.002); at the same time, low-density lipoprotein cholesterol (LDL-C) increased by 53% (from 2.6 to 3.7 mmol/L, P < 0.0001) and apolipoprotein B (apo B) by 35% (from 0.91 to 1.17 g/L, P < 0.0005). In hypothyroidism, the opposite changes were observed: mean Lp(a) decreased from 136 to 114 mg/L (10%, P < 0.02), LDL-C from 4.6 to 3.9 mmol/L (13%, P < 0.01), and apo B from 1.51 to 1.20 g/L (14%, P < 0.01). Although the changes in Lp(a) concentrations did correlate with changes of LDL-C during treatment of hyperthyroidism (r = 0.43, P < 0.05), and with changes in apo B during thyroxine-substitution therapy for hypothyroidism (r = 0.46, P < 0.05), we observed no associations between Lp(a) and LDL-C or apo B in the euthyroid state. These data cannot rule out the possibility that the thyroid hormone-induced increase in LDL-C receptor activity was responsible for the decreased concentrations of Lp(a) in hyperthyroidism. Given that LDL-C is approximately 30% of the Lp(a) molecule but the changes in Lp(a) concentrations are comparable with those in LDL-C (60% vs 53%), and given that Lp(a) is metabolized by an LDL-C-receptor-independent pathway, the present data suggest a direct effect of thyroid hormones on Lp(a) synthesis.

Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease

1994 ◽  
Vol 40 (4) ◽  
pp. 552-561 ◽  
Author(s):  
L L Wu ◽  
J Wu ◽  
S C Hunt ◽  
B C James ◽  
G M Vincent ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Coronary Risk Factors ◽  
Low Density Lipoprotein Cholesterol ◽  
Relative Odds ◽  
The Mean ◽  
High Concentrations ◽  
Artery Disease

Abstract We measured plasma homocyst(e)ine [H(e)] and other coronary risk factors in 266 patients with early coronary artery disease from 170 families in which two or more siblings were affected and in 168 unmatched controls. The mean H(e) concentration adjusted for significant correlates (serum creatinine, uric acid, and low-density lipoprotein cholesterol) was 12.0 mumol/L in proband cases compared with 10.1 mumol/L in controls (P = 0.0001). Many (17.6%) of the proband cases had H(e) concentrations exceeding the 95th percentile for the controls (relative odds = 4.9, P < 0.001). H(e) among cases was bimodally distributed even after adjustment for concentrations of plasma vitamins. Concordant high H(e) was seen in at least 10 (12%) of 85 families with two or more affected siblings. We conclude that a substantial proportion of early familial coronary artery disease is probably related to production of high concentrations of H(e) by one or more major genes.

P2781How to bridge residual distance to target low-density-lipoprotein cholesterol in stroke patients after initial statin therapy?

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
B P Y Yan ◽  
C K Y Chan ◽  
W H S Lai ◽  
O T L To
Keyword(s):  
Statin Therapy ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Stroke Patients ◽  
High Potency ◽  
Index Stroke ◽  
The Mean ◽  
Residual Distance

Abstract Background Current guidelines recommend intensive low-density-lipoprotein cholesterol (LDL-C) lowering to target LDL-C <1.8mmol/L after ischemic stroke (IS). Residual distance to LDL-C target can help select further treatment options after initial statin therapy. Purpose We aimed to evaluate residual distance to target LDL-C and the proportion of IS patients who are projected to reach target LDL-C by different statin and non-statin lipid lowering strategies. Methods We retrospectively analyzed 5,025 patients admitted with IS or transient ischemic attack who survived 1 year from an academic institution in Hong Kong between Jan 2005 and Sep 2017. Patients were divided into (i) high potency (HP-S; rosuvastatin ≥20mg, atorvastatin ≥40mg or simvastatin ≥80mg); (ii) non-high potency (NHP-S; other statin doses) statin users and (iii) no statin therapy. We calculated the mean distance and percentage LDL-C reduction required to reach target LDL-C. We assumed up-titration from NHP-S to HP-S would further reduce LDL-C by 5–15%; addition of ezetimibe 15–25%; up-titrate to HP-S plus ezetimibe 20–40% and combine statin with proprotein convertase subtilsin-kexin type 9 inhibitor (PCSK-9) 40–60%. Results Of 5,025 patients (56.3% males, mean age 69.1±11.5 years), 62.4% (3134/5025) had LDL-C ≥1.8mmol/L at 12-months after index stroke with 16.7% (839/5025), 80.9% (4064/5025) and 2.4% (122/5025) of patients on no statin, NHP-S and HP-S, respectively. 58.1% (2362/4064) of NHP-S and 60.7% (74/122) of HP-S users did not reach LDL-C target. Among these patients, the mean LDL-C was 2.5±0.6 and 2.8±1.0mmol/L; mean residual distance to target 0.7±0.6 and 1.0±1.0mmol/L; and mean percentage LDL-C reduction required to reach target LDL-C goal was 23.3±15.1% and 29.5±18.1%, respectively. The proportion of NHP-S users projected to reach target LDL-C is 34.9% (824/2362) by up-titrating/switching to HP-S, 57.2% (n=1352/2362) by addition of ezetimibe, 84.5% (n=1997/2362) by up-titration to HP-S plus ezetimibe and 98.6% (2330/2362) with PCSK-9 inhibitor (Figure 1). The proportion of HP-S users projected to reach target LDL-C is 43.2% (32/74) by addition of ezetimibe and 94.6% (70/74) with PCSK-9 inhibitor (Figure 1). Conclusion The use of high-potency statin is low and more than 50% of statin users did not reach target LDL-C at 12-months after index stroke. Combined up-titration to high-potency statin plus addition of ezetimibe is expected to bridge residual distance to target LDL-C in majority of stroke patients. Acknowledgement/Funding Supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme (Asia) Ltd.

scholarly journals Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS)

2018 ◽  
Vol 25 (10) ◽  
pp. 1087-1094 ◽  
Author(s):  
Nicolas Danchin ◽  
Wael Almahmeed ◽  
Khalid Al-Rasadi ◽  
Joseph Azuri ◽  
Abdelkrim Berrah ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
High Risk ◽  
Western Europe ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Risk Patients ◽  
C Value ◽  
The Mean

Background Little is known about the achievement of low density lipoprotein cholesterol (LDL-C) targets in patients at cardiovascular risk receiving stable lipid-lowering therapy (LLT) in countries outside Western Europe. Methods This cross-sectional observational study was conducted in 452 centres (August 2015−August 2016) in 18 countries in Eastern Europe, Asia, Africa, the Middle East and Latin America. Patients ( n = 9049) treated for ≥3 months with any LLT and in whom an LDL-C measurement on stable LLT was available within the previous 12 months were included. Results The mean±SD age was 60.2 ± 11.7 years, 55.0% of patients were men and the mean ± SD LDL-C value on LLT was 2.6 ± 1.3 mmol/L (101.0 ± 49.2 mg/dL). At enrolment, 97.9% of patients were receiving a statin (25.3% on high intensity treatment). Only 32.1% of the very high risk patients versus 51.9% of the high risk and 55.7% of the moderate risk patients achieved their LDL-C goals. On multivariable analysis, factors independently associated with not achieving LDL-C goals were no (versus lower dose) statin therapy, a higher (versus lower) dose of statin, statin intolerance, overweight and obesity, female sex, neurocognitive disorders, level of cardiovascular risk, LDL-C value unknown at diagnosis, high blood pressure and current smoking. Diabetes was associated with a lower risk of not achieving LDL-C goals. Conclusions These observational data suggest that the achievement of LDL-C goals is suboptimal in selected countries outside Western Europe. Efforts are needed to improve the management of patients using combination therapy and/or more intensive LLTs.

scholarly journals On the Severity of Carpal Tunnel Syndrome: Metabolic Syndrome or Obesity

2020 ◽  
Vol 8 (A) ◽  
pp. 606-610
Author(s):  
Angelo Vasiliadis ◽  
George Charitoudis ◽  
Theofanis Kantas ◽  
George Giovanidis ◽  
George Biniaris
Keyword(s):  
Metabolic Syndrome ◽  
Waist Circumference ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Low Density Lipoprotein Cholesterol ◽  
Cholesterol Levels ◽  
Tunnel Syndrome ◽  
The Mean ◽  
The Relationship

AIM: This study aimed to determine the relationship between CTS, metabolic syndrome and obesity and to compare the severity of CTS between patients with or without metabolic syndrome (MS) and patients with or without obesity. METHODS: In this prospective study, patients with clinical and electrophysiological confirmed diagnosis of CTS were included. The waist circumference, blood pressure, fasting blood glucose, fasting triglycerides and high/low density lipoprotein cholesterol levels were recorded. Patients were categorized having metabolic syndrome according to Adult Treatment Panel III definition, while body mass index was used to identify obesity. RESULTS: A total of 65 patients with a mean age of 58.91 ± 12.49 years were included. MS was found in 39 (60%) patients and obesity in 27 (41.5%) patients. The CTS was described as mild, moderate and severe in 8, 12 and 19 hands of those with MS and in 2, 6, and 18 of those without MS respectively (p = 0.207). There were no statistically significant results observed between BMI and the severity of CTS (p > 0.05). The mean waist circumference was 94.75 ± 7.36, 98.78 ± 9.64, 106.42 ± 10.78, 86.41 ± 6.77 for patients with MS+_O–, MS–O+_, MS+_O+_ _and MS–O– _respectively (p < 0.002). CONCLUSION: CTS appears to be more severe in patients with MS than in patients with obesity. Central obesity is one of the well-known risk factors for CTS, but components of MS may have a greater effect on the severity of CTS.

scholarly journals Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer

2021 ◽  
Author(s):  
Qingqing Lin ◽  
Wenchao Liu ◽  
Song Xu ◽  
Liping Sun
Keyword(s):  
Ovarian Cancer ◽  
High Density Lipoprotein ◽  
Serum Lipids ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Kaplan Meier ◽  
Low Levels

Abstract Background The effect of serum lipids on ovarian cancer is controversial. We conduct this study to evaluate the prognostic value of preoperative plasma lipid profile in patients with ovarian cancer. Methods The medical records of 156 epithelial ovarian cancer patients who underwent surgical resection in our department were retrospectively reviewed and analyzed. Serum lipids profiles, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), apolipoprotein A-Ⅰ (apoA-Ⅰ), apolipoprotein B (apoB) and clinicopathologic data were analyzed. Cox proportional hazards regression analyses and Kaplan-Meier method were performed to evaluate the overall survival (OS) and progression-free survival (PFS). Results Multivariable Cox regression analysis found that preoperative higher LDL-C level was significantly associated with worse OS (HR 2.088, 95% CI 1.052–4.147, p = 0.035), whereas higher HDL-C level showed significant association with better PFS (HR 0.491, 95% CI 0.247–0.975, p = 0.042). Further Kaplan–Meier survival analysis demonstrated that OS was longer for patients with low levels of LDL-C (< 2.76 mmol/L) compared to those with high levels of LDL-C (≥ 2.76 mmol/L) (P = 0.028), and PFS was better for patients with high levels of HDL-C (≥ 1.19 mmol/L) compared to those with low levels of HDL-C (< 1.19 mmol/L) (P = 0.001). Conclusions Preoperative HDL-C and LDL-C levels are significant predictors of clinical outcome in patients with epithelial ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document